Submission of audited financial results for the quarter and financial year ended 3st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 3.3 pts less than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Johnson Pharmacare Ltd reported a massive loss of Rs 5,561.06 lakhs for FY2026, a dramatic increase from Rs 58.38 lakhs loss in FY2025. Total income was merely Rs 158.10 lakhs. The company had borrowings of Rs 2,140.04 lakhs (inter-corporate deposits) and significant investments. Operating cash outflows were Rs 5,745.54 lakhs with cash losses of Rs 11,123.52 lakhs in the current year versus Rs 58.38 lakhs previously. The statutory auditors from VRSK & Associates issued a qualified opinion citing non-provision of interest on loans, non-compliance with IND-AS, and failure to provide a true and fair view. The auditors also flagged that the company cannot meet its liabilities falling due within one year from the balance sheet date. There was a mid-year auditor change from the predecessor firm. The company appears to be an unregistered lending entity.
The stock carries extreme risk. The auditors have raised serious concerns about the company's ability to continue as a going concern, flagged material uncertainty on meeting near-term obligations, and issued a qualified opinion on financial statements that lack transparency. Shareholders should exercise extreme caution as the company appears to be in severe financial distress.